Medigene to participate in two international conferences

Press Release



Martinsried/Munich, 15 June, 2015. Medigene AG (MDG1, Frankfurt, Prime Standard) announces its participation in two further conferences:

  • BIO International Convention - The Global Event for Biotechnology

            Date: 15 - 18 June 2015
            Location: Philadelphia, USA

  • ODDO SEYDLER BANK Munich Biotech Days

            Date: 1 - 2 July 2015
            Location: Munich, Germany

Medigene AG is a publicly listed (Frankfurt: MDG1, prime standard) biotechnology company headquartered in Martinsried near Munich, Germany. Medigene concentrates on the development of personalized T cell immunotherapies with a focus on haematological malignancies. Medigene is the first German biotech company to have revenues from a marketed product, which is distributed by commercial partner companies. Medigene has advanced drug candidates which are licensed to partners and additional candidates in clinical development. The company is developing highly innovative treatment platforms concentrating on cancer and autoimmune diseases. For more information, please visit

This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene® EndoTAG® and Veregen® are registered trademarks of Medigene AG. These trademarks may be owned or licensed in select locations only.

Contact Medigene
Julia Hofmann, Anja Clausnitzer
Tel.: +49 - 89 - 20 00 33 - 33 01

To unsubscribe from the press release distribution list, please visit: